What's the effect of coffee polyphenols on longevity?

Coffee polyphenols — mainly chlorogenic acids — are among the most consumed antioxidants in the world in high coffee-drinking countries. Large-scale epidemiological studies suggest that regular coffee consumption is associated with a reduction in all-cause mortality (up to 15–20 % for 3 to 5 cups per day according to some meta-analyses) and a reduced risk of several chronic diseases linked to oxidation and inflammation. These associations are consistent with identified biological mechanisms, though a formal causal link is not yet established.

Coffee is one of the primary sources of polyphenols in the diet of Western countries. In high coffee-consuming nations like Finland, Scandinavia or Brazil, coffee can account for up to 70 % of total dietary polyphenol intake. This quantitative importance explains why epidemiologists pay close attention to coffee as a long-term health marker.

Chlorogenic acids (CGA) form the main polyphenolic fraction: 5-CQA (5-caffeoylquinic acid), 3-CQA, 4-CQA, and several dicaffeoylquinic isomers. An espresso typically contains 100 to 200 mg CGA, a filter coffee 150 to 300 mg. After ingestion, roughly 30 % are absorbed in the small intestine, the rest reaching the colon where they are metabolised by the microbiota into biologically active phenolic acids and catechols.

The antioxidant mechanisms are well documented in vitro: CGAs neutralise free radicals, chelate pro-oxidant metal ions (ferrous iron, cuprous copper), and inhibit LDL oxidation. They also activate the Nrf2 signalling pathway — a transcription factor that induces the expression of over 200 endogenous antioxidant defence genes (including superoxide dismutase, catalase and glutathione peroxidase). This activation of the endogenous antioxidant system is considered more powerful than direct antioxidant action.

The epidemiological data are strongest for all-cause mortality. The meta-analysis by Poole et al. (BMJ, 2017), covering 201 meta-analyses and millions of participants, concluded that 3 to 4 cups of coffee per day were associated with the greatest risk reduction: −17 % all-cause mortality, −19 % cardiovascular mortality, −18 % cancer, and significant reductions for type 2 diabetes, liver diseases (including cirrhosis, −39 %), and neurodegenerative diseases.

For liver diseases, the association is particularly strong and biologically plausible. The liver is the first organ to process absorbed polyphenols. Histological studies have shown that regular coffee drinkers present less hepatic fibrosis and reduced liver enzyme activity (AST, ALT). Coffee appears to protect against progression to cirrhosis in patients with NAFLD (non-alcoholic fatty liver disease).

For type 2 diabetes, CGAs improve insulin sensitivity by inhibiting glucose-6-phosphatase (reducing hepatic glucose production) and stimulating the GLUT-4 transporter. A meta-analysis of 28 prospective studies (2014) found a 25 % risk reduction for 3 to 4 cups per day consumers.

An important caveat: these epidemiological studies do not prove causality. Confounding factors (coffee drinkers may have other healthy habits, or chronically ill patients may reduce their intake) can bias associations. Mendelian randomisation studies — using genetic variants as proxies for coffee consumption — have yielded more mixed but broadly consistent results with observational associations for liver diseases and diabetes.

Coffee–longevity associations: meta-analysis summary (Poole et al., BMJ 2017 + supplementary studies)